Quantessence Capital’s Biohaven BHVN Stock Holding History

Quantessence Capital’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-62,979	Closed	-$945K	–	34
2025 Q3	$945K	Buy	+62,979	New	+$917K	0.3%	78

Other funds holding BHVN

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $173M AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Quantessence Capital's BHVN Position: Q4 2025 in Review

Quantessence Capital sold out of Biohaven (BHVN) in Q4 2025, closing a stake of 62,979 shares — an estimated $945K sold.

Quantessence Capital first reported a position in BHVN in Q3 2025 and held it in 1 quarter. The position peaked at $945K in Q3 2025. 272 funds tracked by Wall St. Rank hold BHVN as of Q4 2025.

Quantessence Capital reported no remaining Biohaven position as of Q4 2025 after selling out during the quarter.
Quantessence Capital sold 62,979 Biohaven shares in Q4 2025, an estimated $945K.
Quantessence Capital first reported a position in Biohaven in Q3 2025 and held it in 1 quarter.
Quantessence Capital's Biohaven position peaked at $945K in Q3 2025.
272 funds tracked by Wall St. Rank held Biohaven as of Q4 2025.

Based on Quantessence Capital's 13F filing for Q4 2025, filed 17 Feb 2026.